bms-986326
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2021 (NCT04736134)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
MAPKAPK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06248814 | Phase 1 | Mar 6, 2024 | Bristol-Myers Squibb |
| NCT06013995 | Phase 1 | Sep 21, 2023 | Bristol-Myers Squibb |
| NCT04736134 | Phase 1 | Mar 3, 2021 | Bristol-Myers Squibb |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1